BMJ  2004;329:828 (9 October), doi:10.1136/bmj.38237.585000.7C (published 30 September 2004)

Primary care

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

¹ NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Children's Hospital at Westmead, Westmead, NSW 2145, Australia, ² Department of Emergency and Organ Transplantation, Section of Nephrology, University of Bari, Italy

Objective To evaluate the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (AIIRAs) on renal outcomes and all cause mortality in patients with diabetic nephropathy.

Data sources Medline, Embase, the Cochrane controlled trials register, conference proceedings, and contact with investigators.

Study selection Trials comparing ACE inhibitors or AIIRAs with placebo or with each other in patients with diabetic nephropathy.

Data extraction Mortality, renal outcomes (end stage renal disease, doubling of serum creatinine concentration, prevention of progression of microalbuminuria to macroalbuminuria, remission of microalbuminuria), and quality of trials.

Data synthesis 36 of 43 identified trials compared ACE inhibitors with placebo (4008 patients), four compared AIIRAs with placebo (3331 patients), and three compared ACE inhibitors with AIIRAs (206 patients). We obtained unpublished data for 11 trials. ACE inhibitors significantly reduced all cause mortality (relative risk 0.79, 95% confidence interval 0.63 to 0.99) compared with placebo but AIIRAs did not (0.99, 0.85 to 1.17), although baseline mortality was similar in the trials. Both agents had similar effects on renal outcomes. Reliable estimates of the unconfounded relative effects of ACE inhibitors compared with AIIRAs could not be obtained owing to small sample sizes.

Conclusion Although the survival benefits of ACE inhibitors for patients with diabetic nephropathy are known, the relative effects of ACE inhibitors and AIIRAs on survival are unknown owing to the lack of adequate head to head trials.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Renal complications of childhood type 1 diabetes

Jean-Claude Carel and Claire Levy-Marchal
BMJ 2008 336: 677-678. [Extract] [Full Text] [PDF]

Angiotensin receptor blockers and myocardial infarction: Results reflect different cardiovascular states in patients with types 1 and 2 diabetes

Edmund J Lewis on behalf of the Collaborative Study Group
BMJ 2005 330: 1269-1270. [Extract] [Full Text]

Angiotensin receptor blockers and myocardial infarction: Direct comparative studies are needed

Lionel H Opie
BMJ 2005 330: 1270. [Extract] [Full Text]

Use ACE inhibitors in patients with diabetic nephropathy
BMJ 2004 329: 0. [Full Text]

This article has been cited by other articles:

• Abaterusso, C., Lupo, A., Ortalda, V., De Biase, V., Pani, A., Muggeo, M., Gambaro, G. (2008). Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease. CJASN 3: 1185-1194 [Abstract] [Full text]  
• Chapman, A. B. (2008). Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies. CJASN 3: 1197-1204 [Abstract] [Full text]  
• Almerie, M Q, Williams, R M, Acerini, C L (2008). SHOULD ANGIOTENSIN CONVERTING ENZYME INHIBITORS BE USED IN CHILDREN WITH TYPE 1 DIABETES AND MICROALBUMINURIA?. Arch. Dis. Child. 93: 633-635 [Full text]  
• Norris, S. L., Kansagara, D., Bougatsos, C., Fu, R. (2008). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 855-868 [Abstract] [Full text]  
• Miller, D. R., Oliveria, S. A., Berlowitz, D. R., Fincke, B. G., Stang, P., Lillienfeld, D. E. (2008). Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors. Hypertension 51: 1624-1630 [Abstract] [Full text]  
• Postma, M. J., Boersma, C., Gansevoort, R. T. (2008). Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 23: 1103-1106 [Full text]  
• Mann, N P (2008). How has research in the past 5 years changed my clinical practice?. Arch. Dis. Child. 93: 327-330 [Full text]  
• Carel, J.-C., Levy-Marchal, C. (2008). Renal complications of childhood type 1 diabetes. BMJ 336: 677-678 [Full text]  
• Perkovic, V., Ninomiya, T., Arima, H., Gallagher, M., Jardine, M., Cass, A., Neal, B., MacMahon, S., Chalmers, J. (2007). Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study. J. Am. Soc. Nephrol. 18: 2766-2772 [Abstract] [Full text]  
• Saweirs, W. W. M., Goddard, J. (2007). What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease. Nephrol Dial Transplant 22: ix31-ix38 [Full text]  
• Campbell, H. M, Boardman, K. D, Dodd, M. A, Raisch, D. W (2007). Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model. The Annals of Pharmacotherapy 41: 1101-1110 [Abstract] [Full text]  
• Donnelly, R., Manning, G. (2007). Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. Journal of Renin-Angiotensin-Aldosterone System 8: 13-22 [Abstract]  
• McFarlane, P. A (2006). Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy. Evid. Based Med. 11: 144-144 [Full text]  
• Sarkar, P., Nicholson, G., Hall, G. (2006). Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].. Canadian J. Anesthesia 53: 994-1003 [Abstract] [Full text]  
• Mann, J. F. E., McClellan, W. M., Kunz, R., Ritz, E. (2006). Progression of renal disease--can we forget about inhibition of the renin-angiotensin system?. Nephrol Dial Transplant 21: 2348-2351 [Full text]  
• Stone, M. L., Craig, M. E., Chan, A. K., Lee, J. W., Verge, C. F., Donaghue, K. C. (2006). Natural History and Risk Factors for Microalbuminuria in Adolescents With Type 1 Diabetes: A longitudinal study.. Diabetes Care 29: 2072-2077 [Abstract] [Full text]  
• Griffin, K. A., Bidani, A. K. (2006). Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade. CJASN 1: 1054-1065 [Abstract] [Full text]  
• Tsuyuki, R. T., McDonald, M. A. (2006). Response to Tsuyuki and McDonald. Circulation 114: 855-860 [Full text]  
• Jones, C., Roderick, P., Harris, S., Rogerson, M. (2006). Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 21: 2133-2143 [Abstract] [Full text]  
• Navaneethan, S. D., Querques, M., Bonifati, C., Strippoli, G. F. M. (2006). Antihypertensive Agents in Patients With Diabetes: Trade-off Between Renal and Cardiovascular Protection.. The Diabetes Educator 32: 596-602 [Abstract] [Full text]  
• Strauss, M. H., Lonn, E., Verma, S. (2006). Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply. Eur Heart J 27: 1507-1508 [Full text]  
• MacGregor, M.S., Boag, D.E., Innes, A. (2006). Chronic kidney disease: evolving strategies for detection and management of impaired renal function. QJM 99: 365-375 [Abstract] [Full text]  
• Deckers, J. W., Goedhart, D. M., Boersma, E., Briggs, A., Bertrand, M., Ferrari, R., Remme, W. J., Fox, K., Simoons, M. L., on behalf of the EUROPA Investigators, (2006). Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 27: 796-801 [Abstract] [Full text]  
• Stumpf, J. L, Shehab, N., Patel, A. C (2006). Safety of Angiotensin-Converting Enzyme Inhibitors in Patients with Insect Venom Allergies. The Annals of Pharmacotherapy 40: 699-703 [Abstract] [Full text]  
• Barnett, A. (2006). Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial. J. Am. Soc. Nephrol. 17: S132-S135 [Abstract] [Full text]  
• Vora, J., Weston, C. (2006). BENEDICT: primary prevention of microalbuminuria in hypertensive type 2 diabetes: Bergamo NEphrologic Diabetes Complication Trial (BENEDICT). British Journal of Diabetes & Vascular Disease 6: 84-88  
• Levey, A. S., Uhlig, K. (2006). Which Antihypertensive Agents in Chronic Kidney Disease?. ANN INTERN MED 144: 213-215 [Full text]  
• Strauss, M. H., Lonn, E. M., Verma, S. (2005). Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 26: 2351-2353 [Full text]  
• Krentz, A. J (2005). Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control. British Journal of Diabetes & Vascular Disease 5: 303-304  
• Donnelly, R. (2005). Review: Managing cardiovascular risk in patients with diabetes. British Journal of Diabetes & Vascular Disease 5: 325-329 [Abstract]  
• O'Riordan, S. (2005). Chronic kidney disease and older people--implications of the publication of the Part 2 of the National Service Framework for Renal Services. Age Ageing 34: 546-548 [Full text]  
• Strippoli, G. F.M., Craig, M., Schena, F. P., Craig, J. C. (2005). Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy. J. Am. Soc. Nephrol. 16: 3081-3091 [Abstract] [Full text]  
• Verma, S., Leiter, L. A., Lonn, E. M., Strauss, M. H. (2005). Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. Eur Heart J 26: 1347-1349 [Full text]  
• Boger, R. H, Schwedhelm, E., Maas, R., Quispe-Bravo, S., Skamira, C. (2005). ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc Med 10: S97-S102 [Abstract]  
• Lerma, E. V (2005). Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy. Evid. Based Med. 10: 77-77 [Full text]  
• Opie, L. H (2005). Angiotensin receptor blockers and myocardial infarction: Direct comparative studies are needed. BMJ 330: 1270-1270 [Full text]  
• Lewis, E. J, on behalf of the Collaborative Study Group, (2005). Angiotensin receptor blockers and myocardial infarction: Results reflect different cardiovascular states in patients with types 1 and 2 diabetes. BMJ 330: 1269-1270 [Full text]  
• Boger, R. H, Schwedhelm, E., Maas, R., Quispe-Bravo, S., Skamira, C. (2005). ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc Med 10: S97-S102 [Abstract]  
• Verma, S., Strauss, M. (2004). Angiotensin receptor blockers and myocardial infarction. BMJ 329: 1248-1249 [Full text]  
• (2004). ACE Inhibitors vs. ARBs in Patients with Diabetic Nephropathy: A Meta-Analysis. JWatch General 2004: 2-2 [Full text]  

Rapid Responses:

Read all Rapid Responses

Single Patient Based Medicine, besides EBM, in bed-side assessing ACE-inhibitor action mechanisms.

Sergio Stagnaro
bmj.com, 8 Oct 2004 [Full text]

inclusion criteria

tom m zipp
bmj.com, 14 Oct 2004 [Full text]

ACEI vs. ARB in Diabetic Nephropathy: The Evidence

Maarten W. Taal, et al.
bmj.com, 15 Oct 2004 [Full text]

Effects of ACEI and ARB in diabetic nephropathy

Johannes F. Mann
bmj.com, 20 Oct 2004 [Full text]

ACE-I and ARB meta-analysis incomprehensible

Roland W McCallum
bmj.com, 5 Nov 2004 [Full text]

rats and mice and men

Alfred N Jackson
bmj.com, 20 Nov 2004 [Full text]

ACE inhibitors or Angiotensin II Receptor Blockers: What is Better ?

Dhanashree Kelkar, MD
bmj.com, 1 Dec 2004 [Full text]

Authors' reply to responses

Giovanni FM Strippoli, et al.
bmj.com, 4 Jan 2005 [Full text]